http://orcid.org/0000-0002-1890-1005
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Xiangzhong Xue, Bang Truong & Jingjing Qian. (2023) Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States. Expert Opinion on Biological Therapy 23:8, pages 841-849.
Read now
Read now
Nika Kianfar, Shayan Dasdar, Hamidreza Mahmoudi, Soheil Tavakolpour, Kamran Balighi & Maryam Daneshpazhooh. (2022) Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. Journal of Dermatological Treatment 33:2, pages 869-874.
Read now
Read now
Federico Bardazzi, Camilla Loi, Giulio Vara, Annalisa Patrizi & Ambra Di Altobrando. (2022) Efficacy and safety of biosimilar rituximab in the treatment of pemphigus vulgaris: a single center experience of 12 cases. Journal of Dermatological Treatment 33:1, pages 580-582.
Read now
Read now
Soheil Tavakolpour, Zeinab Aryanian, Farnoosh Seirafianpour, Milad Dodangeh, Ifa Etesami, Maryam Daneshpazhooh, Kamran Balighi, Hamidreza Mahmoudi & Azadeh Goodarzi. (2021) A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns. Immunopharmacology and Immunotoxicology 43:5, pages 507-518.
Read now
Read now
Articles from other publishers (17)
Hamidreza Mahmoudi, Roja Toosi, Ali Salehi Farid & Maryam Daneshpazhooh. (2023) Pemphigus Disease and Area Index: Unmet needs in the real‐world management of pemphigus. Oral Diseases.
Crossref
Crossref
Ali Nili, Shakiba Karimi, Ali Salehi Farid, Pedram Molhem Azar, Zeinab Farimani, Haneyeh Shahbazian, Kamran Balighi, Soheil Tavakolpour, Hamidreza Mahmoudi & Maryam Daneshpazhooh. (2022) Factors associated with the healing time of pemphigus vulgaris oral lesions: A prospective study. Oral Diseases 29:5, pages 2248-2255.
Crossref
Crossref
Elham Mazaherpour, Nika Kianfar, Shayan Dasdar, Mojtaba Sedaghat, Hassan Seyrafi, Kamran Balighi, Fatemeh Saberi, Ali Nili, Zeinab Farimani, Pedram Molhem Azar, Hamidreza Mahmoodi, Dedee F. Murrell & Maryam Daneshpazhooh. (2022) Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients. Dermatologic Therapy 35:12.
Crossref
Crossref
Fateme Shirzad Moghadam, Nika Kianfar, Shayan Dasdar, Rana Samii, Zeinab Farimani, Pedram Molhem Azar, Kamran Balighi, Robabeh Abedini, Tahereh Soori, Ali Salehi Farid, Hamidreza Mahmoudi & Maryam Daneshpazhooh. (2022)
Adverse outcome and severity of
COVID
‐19 in patients with autoimmune bullous diseases: A historical cohort study
. Dermatologic Therapy 35:9.
Crossref
Crossref
Michelle K. Y. Chen, Ravi Vissapragada, Norma Bulamu, Monisha Gupta, Victoria Werth & Deshan Frank Sebaratnam. (2022) Cost-Utility Analysis of Rituximab vs Mycophenolate Mofetil for the Treatment of Pemphigus Vulgaris. JAMA Dermatology 158:9, pages 1013.
Crossref
Crossref
Joško Miše, Ines Lakoš Jukić & Branka Marinović. (2022) Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study. Frontiers in Immunology 13.
Crossref
Crossref
Kamran Balighi, Nazanin Ashtar Nakhaei, Maryam Daneshpazhooh, Zeinab Aryanian, Saeed Aslani, Shadi Balighi & Arghavan Azizpour. (2022) Pemphigus patients with initial negative levels of anti‐desmoglein: A subtype with different profile?. Dermatologic Therapy 35:4.
Crossref
Crossref
Maryam Daneshpazhooh, Soheil Tavakolpour, Ali Salehi Farid, Mehrnoosh Ebadi, Ali Nili, Mohammad Rashidian & Hamidreza Mahmoudi. (2021) Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus. International Journal of Dermatology 61:1.
Crossref
Crossref
Branka Marinović, Joško Miše, Ines Lakoš Jukić & Zrinka Bukvić Mokos. (2021) Pemphigus—The Crux of Clinics, Research, and Treatment during the COVID-19 Pandemic. Biomedicines 9:11, pages 1555.
Crossref
Crossref
Gabrielle Benesh, Tyler M. Andriano & Steven R. Cohen. (2021) Pemphigus vulgaris successfully treated with ocrelizumab following rituximab allergy. JAAD Case Reports 16, pages 12-15.
Crossref
Crossref
G. Ho, T. Sheriff, M. Doria‐Ruiz, Y. Loh & D. F. Murrell. (2021) Are biosimilars for pemphigus safe?. Clinical and Experimental Dermatology 46:5, pages 942-943.
Crossref
Crossref
Gérôme Bohelay, Frédéric Caux & Philippe Musette. (2021) Clinical and biological activity of rituximab in the treatment of pemphigus. Immunotherapy 13:1, pages 35-53.
Crossref
Crossref
Hamidreza Mahmoudi, Soheil Tavakolpour, Kamran Balighi, Ali Salehi Farid, Ali Nili, Delnavaz Jan & Maryam Daneshpazhooh. (2020) Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatologic Therapy 34:1.
Crossref
Crossref
Maryam Daneshpazhooh & HamidReza Mahmoudi. (2021) COVID-19: The experience from Iran. Clinics in Dermatology 39:1, pages 23-32.
Crossref
Crossref
Farzane Farzadfard, Maryam Poursadeghfard & Nahid Ashjazadeh. (2020) Infusion-Related, Short-term, and Delayed Side Effects of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Shiraz E-Medical Journal 22:3.
Crossref
Crossref
Ebrahim Mazloom, Maryam Daneshpazhooh, Raheleh Shokouhi Shoormasti, Kamran Balighi, Hamidreza Mahmoudi, Masoud Moradi Ketisari, Vahid Eslami Faresani & Narges Ghandi. (2020) Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study. Dermatologic Therapy 33:6.
Crossref
Crossref
Maryam Daneshpazhooh, Kamran Balighi, Hamidreza Mahmoudi, Soheil Tavakolpour, Robabeh Abedini, Tahereh Soori, Amir‐Houshang Ehsani, Maryam Ghiasi, Pedram Noormohammadpour, Narges Ghandi, Vahideh Lajevardi, Ali Sadeghinia, Maryam Nasimi, Arghavan Azizpour & Cheyda Chams‐Davatchi. (2019) Iranian guideline for rituximab therapy in pemphigus patients. Dermatologic Therapy 32:5.
Crossref
Crossref